---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-004089"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:33:23.963848+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics provides corporate update; debt reduced by $3.1M, IND planned for Q4 2026

## Summary
- Term debt and notes payable reduced to $0.7M at Dec 31, 2025, from $3.8M at Dec 31, 2024 (unaudited).
- G&A expenses cut by $2.3M in first nine months of 2025 vs same period 2024.
- Plans to file IND for CLD-401 in Q4 2026 targeting NSCLC, triple-negative breast, and head/neck cancer.
- Expects proof-of-concept data for RedTail platform in non-oncology indications and BiTE delivery with T-cell amplifiers.
- New CEO Eric Poma, PhD (appointed 2025) and CMO Guy Travis Clifton, MD bring biopharma experience.

## SEC filing metadata
- accession: 0001493152-26-004089
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315226004089/0001493152-26-004089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315226004089/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-004089
- JSON: https://secwatch.observer/filing/0001493152-26-004089.json
- Plain text: https://secwatch.observer/filing/0001493152-26-004089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.